Orchestra BioMed Holdings, Inc. Investor Brief

Orchestra BioMed Holdings, Inc. is navigating the complex medical device landscape with an 'asset-light' strategy, aiming to revolutionize cardiovascular care. This summary provides investors with a clear, concise overview of the company's latest annual report, highlighting its business model, financial performance, strategic achievements, and key risks.

Business Overview

Orchestra BioMed is an innovative medical device company developing and commercializing therapies for cardiovascular and other widespread diseases. The company employs an 'asset-light' strategy, partnering with larger firms for product development, regulatory approval, and commercialization. This model allows Orchestra BioMed to retain substantial economic upside through royalties and milestone payments.

Its primary assets are:

• AVIM Therapy: A drug-eluting balloon technology that aims to improve outcomes for patients with peripheral artery disease (PAD) and coronary artery disease (CAD). This therapy forms the core of its partnership with Medtronic.
• Virtue SAB Products: A sustained-release drug delivery system, which Ligand Pharmaceuticals is currently advancing through their collaboration.

Financial Performance

For the fiscal year ended December 31, 2024, Orchestra BioMed reported total revenue of approximately $12.5 million, primarily from partnership milestones and limited product sales. This marks a 25% increase from the previous year, driven by achieving specific development milestones with partners.

As a development-stage company, Orchestra BioMed continues to incur substantial expenses. It reported a net loss of $68.2 million for 2024, widening from a $55.1 million net loss in 2023. This increase largely stemmed from intensified research and development (R&D) costs, which reached $45.8 million (up from $38.5 million in 2023). These R&D expenses break down into:

• Clinical R&D ($32.1 million): Funding ongoing human trials for AVIM Therapy and other pipeline candidates.
• Non-clinical R&D ($13.7 million): Supporting early-stage research, lab work, and preclinical studies.

The company's financial performance underscores its strategic focus on advancing its pipeline through significant R&D investment, with revenue generation still in its initial phases.

Risk Factors

Investors should consider several significant risks:

• Regulatory Hurdles: The most immediate risk is the FDA approval of Medtronic's AVIM device. A delay or denial could severely impact the Medtronic partnership, trigger adverse loan repayment terms, and delay market entry and royalty generation.
• Clinical Trial Risk: All medical device development carries inherent risks, including clinical trial failure, unexpected safety issues, or insufficient efficacy data, any of which could halt development or regulatory approval.
• Funding Dependency & Dilution: While successful in 2024, the company will likely need additional capital in the future. An inability to secure funding on favorable terms could impede development. Future equity raises or warrant exercises could also dilute existing shareholders.
• Partnership Reliance: Orchestra BioMed's "asset-light" model makes it highly dependent on partners (Medtronic, Ligand, Terumo) for commercialization. The "Termination And Right Of First Refusal Agreement" with Terumo underscores the possibility of partnership changes or terminations, which could significantly disrupt business plans and revenue streams.
• Intellectual Property Protection: The company's success relies on its ability to protect its proprietary technologies. Challenges to patents or an inability to secure new intellectual property could undermine its competitive advantage.

Management's Discussion and Analysis (MD&A) Highlights

Key Achievements in 2024:

• Strategic Partnerships & Funding: Orchestra BioMed significantly strengthened its financial position and commercialization pathways:
  • Ligand Pharmaceuticals: The company secured a "Revenue Participation Right Purchase and Sale Agreement" in Q2 2024. This agreement entitles Orchestra BioMed to 10% royalties on net sales of AVIM Therapy and Virtue SAB products by Ligand, commencing upon commercial launch. This deal projects substantial recurring revenue post-approval.
  • Medtronic Inc.: Orchestra BioMed entered into a $50 million Convertible Loan Agreement in Q3 2024. This non-dilutive financing is crucial for accelerating the AVIM device's development and regulatory pathway. The loan bears 6% annual interest and is convertible into common stock at $15.00 per share under certain conditions.
  • Terumo Collaboration: Orchestra BioMed extended its "Collaborative Arrangement" with Terumo through 2027. This arrangement focuses on a drug-coated balloon for peripheral artery disease, underscoring the value of this long-standing partnership.
• Capital Raising: The company successfully raised $75 million through private placements in Q1 and Q4 2024, attracting investments from key institutional investors like Perceptive Life Sciences and RTW Investments. Additionally, it utilized an "At-the-Market" (ATM) offering, raising an additional $20 million through opportunistic share sales. These capital injections are vital for funding its R&D pipeline and operational expenses.

Challenges in 2024:

• Heavy Reliance on External Funding: Despite successful capital raises, the company's significant net loss and R&D spend indicate a continued heavy reliance on external financing to sustain operations and advance its pipeline. While typical for biotech, this requires careful management.
• FDA Approval Dependency: A critical condition for the Medtronic convertible loan repayment is FDA approval for Medtronic's AVIM device by December 31, 2025. Failure to secure this approval by the deadline could trigger immediate repayment obligations or other unfavorable terms, introducing significant financial risk.

Leadership and Strategy: Management reported no significant changes in executive leadership or the company's core strategic direction in 2024. Orchestra BioMed remains committed to its 'asset-light' model, focusing on R&D and strategic partnerships to bring innovative therapies to market.

Financial Health

As of December 31, 2024, Orchestra BioMed reported cash and cash equivalents of $95.3 million, providing an operational runway into late 2025. This improved liquidity directly results from successful capital raises.

• Debt Profile: The company's debt includes the $50 million Medtronic Convertible Loan and a $25 million credit facility under a "2024 Loan and Security Agreement" with a commercial bank, which it drew in two tranches. Total debt stands at approximately $75 million.
• Potential Dilution: Orchestra BioMed issued various warrants to sponsors, officers, directors, and partners (including Ligand) over the past year. As of year-end 2024, approximately 8.5 million warrants remained outstanding with various strike prices, predominantly between $10.00 and $12.50. If exercised, these warrants could increase the total number of outstanding shares by up to 20%, potentially diluting the value of existing shares. The private placements and ATM offerings also contributed to an increase in common stock outstanding.

Future Outlook

Looking ahead to 2025 and beyond, Orchestra BioMed's trajectory hinges on several key milestones:

• AVIM FDA Approval: The most critical near-term event is the anticipated FDA approval for Medtronic's AVIM device, targeted for late 2025. This approval could unlock significant value, including the potential for Medtronic's loan conversion and the commencement of royalty streams from Ligand.
• Royalty Generation: As AVIM Therapy and Virtue SAB products gain regulatory approvals and market traction, royalty payments from Ligand Pharmaceuticals could become a significant and growing revenue stream, providing a more stable financial foundation.
• Pipeline Advancement: The company plans to continue advancing its other pipeline candidates, potentially initiating new clinical trials or securing additional development partnerships.
• Continued Capital Management: Orchestra BioMed will actively manage its capital structure, balancing R&D investment with potential future financing needs.

Competitive Position

Orchestra BioMed operates in highly competitive cardiovascular device markets, competing with established players like Boston Scientific, Abbott Laboratories, and other Medtronic divisions that offer drug-eluting stents and balloons. Orchestra BioMed aims to differentiate itself through its unique AVIM drug-eluting balloon technology and Virtue SAB sustained-release drug delivery system, which offer potentially superior clinical outcomes or novel treatment approaches. Its 'asset-light' partnership model also allows it to focus on innovation while leveraging partners' commercial scale.

Market and Regulatory Environment

A stringent and evolving regulatory landscape characterizes the medical device industry, with FDA approval representing the paramount hurdle for market entry. Increasing regulatory scrutiny and complex reimbursement policies are ongoing factors that can impact product timelines and commercial success. However, the global rise in cardiovascular diseases and an aging population present a strong underlying market demand for innovative and effective treatments, which Orchestra BioMed aims to address.